GlassScriptPhysician profile
Gary L Bohay
NPI 1679534887
$13,514.17
in general payments reported to CMS, 2019-2025
56 companies · $2,285 in 2025
The $2,285 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,199 · 2020: $1,672 · 2021: $1,881 · 2022: $1,894 · 2023: $2,075 · 2024: $2,507 · 2025: $2,285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,867.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,592.48 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $1,217.19 | 2019-2025 | Otezla, Repatha, Evenity |
| Abbvie INC. | $1,125.26 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,001.23 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $903.70 | 2019-2025 | Jardiance, Spiriva, Stiolto Respimat |
| Pfizer INC. | $817.29 | 2019-2025 | |
| Lilly USA, LLC | $792.79 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $594.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $507.55 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $431.96 | 2019-2025 | Spravato, Xarelto |
| Merck Sharp & Dohme LLC | $323.96 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $321.12 | 2022-2025 | |
| Allergan, INC. | $269.42 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $260.36 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $236.96 | 2019-2024 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Bohay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.